electroCore (NASDAQ:ECOR – Get Free Report) and Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.
Analyst Recommendations
This is a breakdown of recent recommendations for electroCore and Vivos Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| electroCore | 1 | 1 | 1 | 0 | 2.00 |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
electroCore currently has a consensus price target of $18.00, suggesting a potential upside of 139.36%. Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 2,360.46%. Given Vivos Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Vivos Therapeutics is more favorable than electroCore.
Volatility & Risk
electroCore has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.11, suggesting that its share price is 511% more volatile than the S&P 500.
Valuation and Earnings
This table compares electroCore and Vivos Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| electroCore | $32.03 million | 2.12 | -$13.97 million | ($1.66) | -4.53 |
| Vivos Therapeutics | $20.90 million | 0.08 | -$21.17 million | ($1.90) | -0.06 |
electroCore has higher revenue and earnings than Vivos Therapeutics. electroCore is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares electroCore and Vivos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| electroCore | -39.96% | N/A | -81.35% |
| Vivos Therapeutics | -122.00% | -2,325.64% | -102.01% |
Insider & Institutional Ownership
26.7% of electroCore shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 7.8% of electroCore shares are owned by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
electroCore beats Vivos Therapeutics on 9 of the 14 factors compared between the two stocks.
About electroCore
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
